Six-Year NATALEE Data Show Kisqali Cuts Death Risk 19% in High-Risk Early Breast Cancer
Start here
Novartis has reported six-year follow-up results from the phase 3 NATALEE trial in high recurrence risk HR+/HER2- early breast cancer. Adding Kisqali (ribociclib) to endocrine therapy reduced the risk of death by 19% compared with endocrine therapy alone, with a hazard ratio of 0.809 (95% CI 0.661-0.989). The findings strengthen the case for Kisqali as part of treatment in this population. Open questions include how the survival benefit will translate into regulatory updates, treatment guidelines, and clinical uptake across patient risk subgroups.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickNATALEE Six-Year Follow-up Shows Kisqali Plus Endocrine Therapy Cuts Death Risk 19% in High-Risk HR+/HER2- Early Breast Cancer
Novartis announced six-year follow-up results from the phase 3 NATALEE trial. In patients with high recurrence risk HR+/HER2- early breast cancer, Kisqali (ribociclib) plus endocrine therapy reduced the risk of death by 19% compared with endocrine therapy alone (HR=0.809, 95% CI 0.661-0.989).
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 11:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.